Abstract 2432: The bruton's tyrosine kinase inhibitor ibrutinib synergized with the proteasome inhibitor carfilzomib and overcame immunoproteasome-mediated carfilzomib resistance in mantle cell lymphoma .

2013 ◽  
Author(s):  
Zhishuo Ou ◽  
Liang Zhang ◽  
Kate Newberry ◽  
Luhong Sun ◽  
Kirk J. Christopher ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Proteasome Inhibitor ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Mantle Cell

scholarly journals Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Leukemia ◽  
2019 ◽  
Vol 34 (5) ◽  
pp. 1458-1461 ◽  
Author(s):  
Simon A. Rule ◽  
Guillaume Cartron ◽  
Christopher Fegan ◽  
Franck Morschhauser ◽  
Lingling Han ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Bruton's Tyrosine Kinase ◽  
Mantle Cell ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document